Antidepressant combinations: epidemiological considerations

Agüera, L.; Rojo, J. Emilio; Ros, Silvia Algaba; Gándara, J. de la; Pedro, J. M. de

doi:10.1111/j.1600-0447.2005.00674.x

Cited by 4 publications

(3 citation statements)

References 12 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be due to the characteristics of the patient population in these countries. On the other hand, all investigators in Austria were specialists and may treat depression more aggressively than PCPs to achieve full remission [1]. Moreover, it has been recommended in the UK, for example, that antidepressant combinations should only be initiated under specialist supervision [22].…”

Section: Differences Among Countriesmentioning

confidence: 99%

Prescribing patterns of antidepressants in Europe: Results from the Factors Influencing Depression Endpoints Research (FINDER) study

et al. 2008

View full text Add to dashboard Cite

Antidepressant prescribing patterns and factors influencing the choice of antidepressant for the treatment of depression were examined in the Factors Influencing Depression Endpoints Research (FINDER) study, a prospective, observational study in 12 European countries of 3468 adults about to start antidepressant medication for their first episode of depression or a new episode of recurrent depression. Selective serotonin reuptake inhibitors (SSRIs) were the most commonly prescribed antidepressant (63.3% patients), followed by serotonin-norepinephrine reuptake inhibitors (SNRIs, 13.6%), but there was considerable variation across countries. Notably, tricyclic and tetracyclic antidepressants (TCAs) were prescribed for 26.5% patients in Germany. The choice of the antidepressant prescribed was strongly influenced by the previous use of antidepressants, which was significantly associated with the prescription of a SSRI (OR 0.64; 95% CI 0.54, 0.76), a SNRI (OR 1.49; 95% CI 1.18, 1.88) or a combination of antidepressants (OR 2.78; 95% CI 1.96, 3.96). Physician factors (age, gender, speciality) and patient factors (severity of depression, age, education, smoking, number of current physical conditions and functional syndromes) were associated with initial antidepressant choice in some models. In conclusion, the prescribing of antidepressants varies by country, and the type of antidepressant chosen is influenced by physician- as well as patient-related factors.

show abstract

Section: Differences Among Countriesmentioning

confidence: 99%

Prescribing patterns of antidepressants in Europe: Results from the Factors Influencing Depression Endpoints Research (FINDER) study

et al. 2008

View full text Add to dashboard Cite

show abstract

“…We were alarmed on reading the results of a recent survey of Australian doctors working in mental health that reported that 79% had used combination antidepressants in the treatment of depression 1 . This figure is in stark contrast to rates published from similar international surveys that suggest the use of combination antidepressants is between 2 and 15% 2 . Even in the home of this practice, combination antidepressants appear to be used by only 3% of psychiatrists in the United States 3 .…”

mentioning

confidence: 92%

Combination Antidepressants are not yet Proven Therapy in the Treatment of Depression

Olver¹,

Ellen²,

Norman³

2007

Australas Psychiatry

View full text Add to dashboard Cite

“…There are different reasons why a patient fails to respond or responds only partially to a prescribed antidepressant. These include pharmacogenetic variations, problems associated with the pharmacokinetics of the prescribed drug and possible interactions with other medication, as well as the patient's general state of health and the presence of other psychiatric illness or substance abuse (Agüera, et al, 2005;Wijeratne and Sachdev, 2008).…”

Section: Introductionmentioning

confidence: 99%

Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study

et al. 2009

View full text Add to dashboard Cite

The efficacy of the combination therapy with two antidepressants from different pharmacological families in patients with treatment-resistant depression has been reported in multiple studies. In this prospective 12-weeks open-label study, we assessed the effectiveness of the addition of reboxetine to 79 depressive outpatients diagnosed with major depressive disorder (MDD) according to the DSM-IV criteria who had previously not responded, or had done so only in a partial way, over 8 weeks of conventional treatment, in monotherapy, with duloxetine. Efficacy was assessed using the 21-item Hamilton Depression Rating Scale (HDRS) and the Clinical Global Impression-Improvement (CGI-I). Safety was evaluated by recording spontaneously reported adverse events. Data were analysed on an intent-to-treat basis, using the last-observation-carried-forward method. Mean HDRS reduction was 65.5% (P < 0.0001). The percentages of responders (>or=50% reduction in HDRS) and patients considered benefiting from complete remission (HDRS

show abstract

Antidepressant combinations: epidemiological considerations

Cited by 4 publications

References 12 publications

Prescribing patterns of antidepressants in Europe: Results from the Factors Influencing Depression Endpoints Research (FINDER) study

Prescribing patterns of antidepressants in Europe: Results from the Factors Influencing Depression Endpoints Research (FINDER) study

Combination Antidepressants are not yet Proven Therapy in the Treatment of Depression

Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study

Contact Info

Product

Resources

About